WEHI-345 (WEHI345) is a novel, potent and selective RIPK2 inhibitor with therapeutic potential to treat NOD-driven inflammatory diseases. It inhibits RIPK2 with an IC50 of 0.13 μM and shows NOD signalling events yet prevents inflammatory cytokine production. Intracellular nucleotide binding and oligomerization domain (NOD) receptors recognize antigens including bacterial peptidoglycans and initiate immune responses by triggering the production of pro-inflammatory cytokines through activating NF-κB and MAP kinases. Receptor interacting protein kinase 2 (RIPK2) is critical for NOD-mediated NF-κB activation and cytokine production. WEHI-345 delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement. Despite only delaying NF-κB activation on NOD stimulation, WEHI-345 prevents cytokine production in vitro and in vivo and ameliorates experimental autoimmune encephalomyelitis in mice.

纯度：≥98%

CAS：1354825-58-3